{"disease":{"id":"giardiasis","name":"Giardiasis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"tinidazole","indication_name":"Giardiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tindamax","generic_name":"TINIDAZOLE","company_name":"Mission Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Tindamax works by damaging the DNA of susceptible microorganisms, ultimately leading to their death."},{"drug_id":"metronidazole","indication_name":"Giardiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nitazoxanide","indication_name":"Giardiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alinia","generic_name":"NITAZOXANIDE","company_name":"Romark","drug_phase":"marketed","molecular_target":"Anoctamin-1","drug_class":"Antiprotozoal [EPC]","quality_score":58,"revenue":null,"mechanism":"Alinia works by inhibiting the Anoctamin-1 ion channel, disrupting the parasite's ability to maintain its cellular environment."},{"drug_id":"tinidazole","indication_name":"Giardiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tindamax","generic_name":"TINIDAZOLE","company_name":"Mission Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":"Tindamax works by damaging the DNA of susceptible microorganisms, ultimately leading to their death."},{"drug_id":"secnidazole","indication_name":"Giardiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solosec","generic_name":"SECNIDAZOLE","company_name":"Evofem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":"Solosec works by entering susceptible microorganisms and disrupting their DNA, ultimately leading to cell death."},{"drug_id":"mepacrine","indication_name":"Giardiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"mepacrine","company_name":"","drug_phase":"unknown","molecular_target":"Aldehyde oxidase, Major prion protein, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Giardiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT00001162","title":"Parasitic Infections of the Gastrointestinal Tract","phase":"","overall_status":"TERMINATED","enrollment_count":150,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02736968","title":"Auranofin for Giardia Protozoa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02942485","title":"Treatment of Giardia Lamblia Infections in Children","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}